Abnormalities of chromosome 1 are among the most frequent chromosomal alterations in multiple myeloma (MM), being found in up to 45% of patients. 1, 2 It has been reported that the short arm of chromosome 1 is preferentially involved in deletions, whereas the long arm is associated with amplification. The gain of 1q (1q/gain) can occur as isochromosomes, duplications or jumping translocations. It has been widely reported that 1q/gain MM patients are characterized by complex karyotypes and aggressive disease, and a close association with poor-risk genetic features, such as chromosome 13q deletion (D13) and the t(4;14) translocation has also been described. 1 It has been recently demonstrated that gains/amplification of 1q21 increase as the condition goes from smoldering to overt MM, thus suggesting that these regions contain critical genes for disease progression. 2 These findings along with the limited information concerning specific transcriptional profiles prompted us to molecularly characterize 1q/gain MMs by FISH and microarray analyses.
Our study includes a panel of 77 MM patients at diagnosis, whose characteristics have been deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GEO; http://www.ncbi.nlm.mih.gov/geo, accession number GSE6401). Bone marrow plasma cells were purified (490% in all cases) using CD138-immunomagnetic bead selection and characterized by FISH for the presence of 11 polisomy, the most recurrent IGH translocations, ploidy status, D13, and global gene expression profiling using the Affymetrix U133A gene chips, as described previously. 3 Patients were then stratified accordingly to the proposed translocation/cyclin D (TC) classification in five groups: TC1 characterized by the t(11;14) or t(6;14) translocations, with the consequent overexpression of either CCND1 or CCND3, and a nonhyperdiploid status; TC2 showing low/moderate levels of the CCND1 gene in the absence of any primary IGH translocations, and a hyperdiploid status; TC3 including tumors that do not fall into any of the other groups, most of which express CCND2; TC4 showing high CCND2 levels and the presence of the t(4;14) translocation and TC5 expressing the highest levels of CCND2 in association with either the t(14;16) or t(14;20) translocation. 3 Assessment of 1q/gain by FISH was performed by using three BAC clones specific for the BCL9 (1q21.1), CKS1B (1q22) and ARF1 (1q42.13) loci, and setting the threshold as 10%. Specific alterations were identified in 40/77 (51.9%) patients; three (75%) or four (12.5%) signals of all the 1q probes were found in 35 patients and, in the remaining five samples (12.5%), the probes mapping to 1q21 and 1q22 showed more signals than that mapping to 1q42. 1q/gain was observed in the majority of purified plasma cells (490%) in all but three patients (range 12-20%). 1q/gain was significantly absent in TC2 group (Po10 À4 ) and present in TC3 (P ¼ 0.008), whereas the correlation was not significant in the TC1 (P ¼ 0.053) or TC4 (P ¼ 0.142) groups; in addition, 1q extra copies significantly associated with D13 (Po10
À4
) and chromosome 11 polisomy (although at a limited significance level of P ¼ 0.038), but not ploidy status (P ¼ 0.0971).
To identify a specific transcriptional fingerprint characterizing 1q/gain, we made a supervised analysis of 1q/gain versus 1q/ normal MM patients using SAM algorithm. Seventy-two probe sets (specific for 61 genes) distinguished the 40 1q/gain from the 37 1q/normal cases ( Figure 1a and Table 1a , b). Notably, in the 1q/gain patients 41 of the 43 upregulated genes mapped to 1q12-q44, whereas a significant percentage of the downregulated genes was localized on chromosomes 13q (7/18; 39%) and 11 (6/18, 33%). To verify whether the 1q/gain reflected transcriptional imbalances of specific chromosomal regions, the expression data from the 1q/gain and 1q/normal samples were also analyzed in the context of the physical localization of the genes using a model-free statistical method (LAP), 4 allowing the identification of five modulated chromosomal regions (Figure 1b ). In the 1q/gain patients, the region 1q21.1-q44 (absolute positions: 146,567,360-245,353,955) was upregulated and 13q12-14 (22,800,966-47,961,101) downregulated, which is in line with the significant association between 1q abnormalities and D13; regional downregulation was also observed in chromosome regions 11p15 (2,380, 098-6,372,930), 11q13-q23 (71,317,730-113,946,523) and 15q24.1-q25 (72,397,963-78,483,746), which may reflect the higher frequency of hyperdiploid patients in the 1q/normal group. 
Table 1a
Forty-three upregulated genes in 1q/gain, ordered by chromosomal location and gene name whenever more than one probe recognized the same gene, the one with the best score is shown Letters to the Editor Notably, the transcriptional fingerprint identified in our database was validated by means of a meta-analysis of a publicly available independent set of 248 MM cases (114 1q/ gain and 134 1q/normal) profiled on Affymetrix HG-U133 2.0 Plus gene chips. 5 A PAM model was designed with all of the probes trained on a random selection of half 1q/gain and 1q/normal patients, and was then used to classify the entire test set into the 1q/gain and 1q/normal groups ( Table 2 ). The classification accuracy measures showed a global classification rate of 85.2% and a mean specificity of 85.5%, suggesting that the identified expression signature is a highly conserved characteristic of the 1q/gain abnormality and is not affected by cohort-or lab-specific biases.
The functional genomic annotation of our selected list was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) Tool 2006 (US National Institutes of Health at http://david.niaid.nih.gov/david/version2/index.htm) and indicated that most of the discriminating genes are involved in a network of specialized biological functions. In particular, the patients with 1q/gain showed upregulation of genes involved in intracellular protein transport, such as COPA and ARF1, which play a role in vesicle-mediated transport from the endoplasmic reticulum (ER) to the Golgi region, as well as a significant overexpression of RABIF and RAB3GAP2 both of which are related to the ubiquitous key regulators of membranevesicle transport Rab GTPases. These findings may also partially account for the increased expression of genes coding for proteins involved in energy production pathways, specifically, the citrate cycle (FH and SDHC), glycogen metabolism (PPP2R5A) and fatty acid oxidation (ADIPOR1) and steroid biosynthesis (ACBD3, PMVK and FDPS). Among the downregulated transcripts in the 1q/gain group, we recognized three genes involved in translational mechanisms (RPLP2, RPL21 and FAU), and the CASP4 gene. In the context of these data, it is worth noting the recent suggestion that B-cell malignancies (including MM) may be highly dependent on ER-Golgi protein transport for their survival and that targeting this process may represent a new therapeutic strategy. This could be a promising approach, especially in these MM cases that poorly respond to current treatments, such as the 1q/gain patients in whom thalidomide uptake does not improve event-free survival. 2 Genes involved in the complex network leading to ER stressinduced responses are also significantly modulated in 1q/gain patients. The upregulation of the CLN3 (chaperone gene), UBAP2L and UBE2Q1 (ubiquitin cycle) and PSMD4 (proteasome degradation) could be seen in the context of the ER stress secondary defensive mechanism called ER-associated protein degradation. Finally, we found the downregulation of CASP4, which has been described as localizing to the ER and specifically initiating apoptosis in response to ER-stress stimuli. In this regard, it has been shown that ER stress-induced apoptosis can play an important role in the sensitivity of malignant cells to certain drugs, including bortezomib. In addition, a recent pilot study using human MM cell lines found that submicromolar concentrations of brefeldin A, an inhibitor of ER-Golgi protein transport currently being developed as a novel anticancer agent, effectively induces apoptosis in MM cells by activating caspase-2, which localizes to the Golgi apparatus. 6 These findings suggest that improving our understanding of ER stress-induced responses may lead to important contributions to treatment strategies.
With regard to currently available literature, the overexpression of COPA, RABIF and ARF1 was reported by Walker et al. 7 in a cohort of 11 1q/gain patients out of 30 MM patients at diagnosis, and overexpression of the COPA gene was also described by Carrasco et al. 8 in the group of hyperdiploid MM with a prevalence of 1q/gain and D13.
In conclusion, these data extend our knowledge of the specific genes/pathways deregulated in MM patients with 1q gain, and also provide an input for further therapeutic strategies in MM. 
